États-Unis · Agences & temps réel · PR Newswire

Henlius reports positive results from ASTRIDE U.S. bridging study for serplulimab in combination with chemotherapy for first-line treatment of patients with extensive-stage small cell lung cancer (ES-SCLC)

Publié par PR Newswire · États-Unis il y a 1 h

ASTRIDE trial for first-line ES-SCLC demonstrated favorable median overall survival in serplulimab with chemotherapy versus atezolizumab plus chemotherapy Study enrolled over 200…

Lire l'article complet sur PR Newswire Connectez-vous pour sauvegarder

MarketNews présente le titre et le résumé publiés par le média. L'article complet se lit sur le site de l'éditeur. (www.prnewswire.com)

Henlius reports positive results from ASTRIDE U.S. bridging study for serplulimab in combination with chemotherapy for first-line treatment of patients with extensive-stage small cell lung cancer (ES-SCLC)

À lire aussi

Pull Up a Chair, Comadre: Melissa Rios Opens La Tiendita and Takes LA Mornings to the Streets

Baby orangutans in India expose illegal wildlife trade as experts question a billionaire’s zoo

Dragonfly On-demand Webinar: Middle East: Anticipating a convergence of conflicts

MT Newswires' MCP Server Now Available in Perplexity Computer, Bringing Real-Time Global Market News to AI-Driven Workflows

Henlius reports positive results from ASTRIDE U.S. bridging study for serplulimab in combination with chemotherapy for first-line treatment of patients with extensive-stage small cell lung cancer (ES-SCLC)

Partager

À lire aussi

Pull Up a Chair, Comadre: Melissa Rios Opens La Tiendita and Takes LA Mornings to the Streets

Baby orangutans in India expose illegal wildlife trade as experts question a billionaire’s zoo

Dragonfly On-demand Webinar: Middle East: Anticipating a convergence of conflicts

MT Newswires' MCP Server Now Available in Perplexity Computer, Bringing Real-Time Global Market News to AI-Driven Workflows